Novo's liraglutide gets CHMP green light for obesity
This article was originally published in Scrip
Executive Summary
Novo Nordisk's GLP-1 agonist product Saxenda (liraglutide) has won a recommendation for regulatory approval from the European Medicine Agency's CHMP for use in obesity. The drug, which is already marketed as Victoza at lower doses for diabetes, is not hampered by safety concerns that have hindered other anorectics, and is thought likely to perform well.